In 1987, the World Health Organization, or WHO, took action to improve the quality of maternal health around the world through the declaration of the Safe Motherhood Initiative, or the SMI, at an international conference concerning maternal mortality in Nairobi, Kenya. Initially, the SMI aimed to reduce the prevalence of maternal mortality around the world, as over 500,000 women died during pregnancy and childbirth annually at the time of its inception, while about 98 percent of those deaths occurred in low-income countries. While WHO led the initiative, many organizations in various countries participated in additional programs in order to implement the goals of the SMI. WHO developed the SMI in order to reduce the prevalence of maternal death, developing one of the first proposals that brought attention to maternal health on a global basis at a time when global maternal mortality was high.

To address the international Human Immunodeficiency Virus epidemic, the World Health Organization, or WHO, developed three drug treatment regimens between 2010 and 2012 specifically for HIV-positive pregnant women and their infants. WHO developed the regimens, calling them Option A, Option B, and Option B+, to reduce or prevent mother-to-child, abbreviated MTC, transmission of HIV. Each option comprises of different types and schedules of antiretroviral medications. As of 2018, WHO reported that in Africa alone about 1,200,000 pregnant women were living with untreated HIV. Those women have up to a forty-five percent chance of transmitting HIV to their offspring if they do not receive treatment. Option B+ has decreased the overall maternal mortality rates in many low- and middle-income countries, and numerous studies have supported the notion that it is the most effective of the three regimens for preventing MTC transmission of HIV.

Menstrual hygiene management, or MHM, is a concept that concerns girls' and women’s access to the appropriate information and resources to manage menstruation. In December 2012, the Joint Monitoring Program, or JMP, was one of the first organizations to define MHM as a global development goal. Since then, other organizations like WaterAid and the United Nations have expanded MHM’s definition to include menstrual education that is biologically accurate and free of taboo and stigma. Many women in low-income countries lack those necessities for MHM due to high prices of menstrual sanitary products, lack of access to clean water and sanitation facilities, and social stigma surrounding menstruation that prevents it from being talked about. However, as more organizations began to frame MHM as an issue of public concern rather than a woman’s private problem, more researchers, organizations, and governmental bodies have begun to address issues at the root of inadequate MHM.

Hans Asperger studied mental abnormalities in children in Vienna, Austria, in the early twentieth century. Asperger was one of the early researchers who studied the syndrome that was later named after him, Asperger's Syndrome. Asperger described the syndrome in his 1944 publication Die Autistischen Psychopathen im Kindesalter (Autistic Psychopathy in Childhood). At that time, the syndrome was called autistic psychopathy, and Asperger noted that characteristics of the syndrome included lack of sympathy, one-sided conversations, and difficulty forming friendships. Asperger's work led to the recognition of Asperger's Syndrome as a disorder that results from abnormal development, and the syndrome was later classed on the autism spectrum.

In 2016, physician researchers Agustin Conde-Agudelo and José Díaz-Rossello published “Kangaroo Mother Care to Reduce Morbidity and Mortality in Low Birthweight Infants,” in which they compared the effectiveness of Kangaroo Mother Care to that of traditional treatments for low birth weight newborns. Physicians began using Kangaroo Mother Care in the 1970s as a treatment for low birth weight infants. The treatment, which involves exclusive breastfeeding and skin-to-skin contact, was created to help mothers care for low birth weight infants in developing. In 2015, the World Health Organization estimated that globally, one million infants died due to complications of low birth weight, and a majority of those deaths occurred in developing countries. In their article, the authors demonstrated that Kangaroo Mother Care is just as effective as conventional medical care.

Physician researchers Edgar Rey Sanabria and Héctor Martínez-Gómez developed the Kangaroo Mother Program in Bogotá, Colombia, in 1979, as an alternative to conventional incubator treatment for low birth weight infants. As of 2018, low birth weight and its associated complications are the leading causes of infant death, especially in developing and underdeveloped countries where access to technology and skilled healthcare providers is limited. Kangaroo Mother Care is a simple and low cost method for treating low birth weight infants. Even though researchers developed Kangaroo Mother Care for infants born in hospitals with limited resources, they demonstrated that the method could be just as effective as conventional treatments. Kangaroo Mother Care changed the standard of care for low birth weight infants, making life-saving medical treatments accessible to thousands of infants in developing and undeveloped countries.

In the 1994 article “The ‘Kangaroo-Method’ for Treating Low Birth Weight Babies in a Developing Country,” authors Nils Bergman and Agneta Jürisoo evaluate the effectiveness of the Kangaroo Care method in treating low birth weight infants at Manama Mission Hospital in Gwanda, Zimbabwe. Low birth weight infants face many medical complications. In developing countries, where the prevalence of low birth weight infants is highest, there is limited access to the technology or skilled personnel required to keep those infants alive. The Kangaroo Care method includes exclusive breastfeeding and skin-to-skin contact on the mother's chest to treat low birth weight infants. In “The ‘Kangaroo-Method’ for Treating Low Birth Weight Babies in a Developing Country,” the authors demonstrate that the method is just as effective as conventional technological methods in treating low birth weight infants.

To address the international Human Immunodeficiency Virus epidemic, the World Health Organization, or WHO, developed three drug treatment regimens between 2010 and 2012 specifically for HIV-positive pregnant women and their infants. WHO developed the regimens, calling them Option A, Option B, and Option B+, to reduce or prevent mother-to-child, abbreviated MTC, transmission of HIV. Each option comprises of different types and schedules of antiretroviral medications. As of 2018, WHO reported that in Africa alone about 1,200,000 pregnant women were living with untreated HIV. Those women have up to a forty-five percent chance of transmitting HIV to their offspring if they do not receive treatment. Option B+ has decreased the overall maternal mortality rates in many low- and middle-income countries, and numerous studies have supported the notion that it is the most effective of the three regimens for preventing MTC transmission of HIV.

In 2021, the World Health Organization, or WHO, published the sixth edition of their Laboratory Manual for the Examination and Processing of Human Semen, which provides standardized guidelines to physicians and other medical professionals performing semen analysis. Semen analysis is a technique that medical professionals use to analyze the characteristics of a male’s semen and sperm cells to identify possible causes of male infertility. A sperm cell is the male sex cell that fertilizes a female’s egg cell, while semen is the fluid containing sperm cells that men release during ejaculation. The WHO created the first laboratory manual for semen analysis in 1980, a time when there was no standardized way to analyze a male’s semen sample. The WHO laboratory manual was one of the first documents to standardize a procedure for evaluating human semen to look for sperm abnormalities, and it remains one of the most widespread methods of evaluating a male’s fertility potential and determining the causes of male infertility.